Towa Pharmaceutical Co., Ltd. (4553T) DCF Valuation

Towa Pharmaceutical Co., Ltd. (4553.T) Valation DCF

JP | Healthcare | Drug Manufacturers - Specialty & Generic | JPX
Towa Pharmaceutical Co., Ltd. (4553T) DCF Valuation
  • Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • Aucune Expertise N'Est Requise; Facile À Suivre

Towa Pharmaceutical Co., Ltd. (4553.T) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Que vous soyez un investisseur ou un analyste, cette calculatrice DCF de DCF Towa Pharmaceutical Co., Ltd. (4553T) est votre outil incontournable pour une évaluation précise. Chargé de données réelles de Towa Pharmaceutical, vous pouvez ajuster les prévisions et observer immédiatement les résultats.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019
AY2
2020
AY3
2021
AY4
2022
AY5
2023
FY1
2024
FY2
2025
FY3
2026
FY4
2027
FY5
2028
Revenue 110,384.0 154,900.0 165,615.0 208,859.0 227,934.0 274,939.6 331,638.8 400,030.9 482,527.0 582,035.9
Revenue Growth, % 0 40.33 6.92 26.11 9.13 20.62 20.62 20.62 20.62 20.62
EBITDA 24,456.0 30,354.0 29,492.0 24,924.0 35,536.0 47,885.0 57,760.0 69,671.5 84,039.5 101,370.5
EBITDA, % 22.16 19.6 17.81 11.93 15.59 17.42 17.42 17.42 17.42 17.42
Depreciation 8,285.0 10,425.0 10,954.0 19,409.0 17,888.0 20,890.3 25,198.4 30,394.9 36,663.0 44,223.9
Depreciation, % 7.51 6.73 6.61 9.29 7.85 7.6 7.6 7.6 7.6 7.6
EBIT 16,171.0 19,929.0 18,538.0 5,515.0 17,648.0 26,994.7 32,561.7 39,276.7 47,376.5 57,146.7
EBIT, % 14.65 12.87 11.19 2.64 7.74 9.82 9.82 9.82 9.82 9.82
Total Cash 18,713.0 22,915.0 32,830.0 24,257.0 29,650.0 41,896.0 50,536.0 60,957.8 73,528.8 88,692.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 41,572.0 45,784.0 50,748.0 54,392.0 71,657.0
Account Receivables, % 37.66 29.56 30.64 26.04 31.44
Inventories 50,415.0 60,951.0 72,701.0 92,927.0 101,072.0 119,738.4 144,431.3 174,216.6 210,144.3 253,481.2
Inventories, % 45.67 39.35 43.9 44.49 44.34 43.55 43.55 43.55 43.55 43.55
Accounts Payable 10,691.0 11,869.0 17,041.0 31,284.0 26,372.0 29,795.6 35,940.2 43,351.9 52,292.1 63,076.1
Accounts Payable, % 9.69 7.66 10.29 14.98 11.57 10.84 10.84 10.84 10.84 10.84
Capital Expenditure -4,670.0 -9,879.0 -13,576.0 -30,469.0 -39,325.0 -27,849.6 -33,592.9 -40,520.6 -48,876.9 -58,956.5
Capital Expenditure, % -4.23 -6.38 -8.2 -14.59 -17.25 -10.13 -10.13 -10.13 -10.13 -10.13
Tax Rate, % 33.88 33.88 33.88 33.88 33.88 33.88 33.88 33.88 33.88 33.88
EBITAT 11,324.9 14,853.1 13,261.4 2,635.9 11,669.4 17,817.5 21,491.8 25,924.0 31,270.2 37,718.8
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -66,356.1 1,829.1 -902.6 -18,051.1 -40,089.6 -18,146.2 -23,066.5 -27,823.3 -33,561.2 -40,482.3
WACC, % 3.74 3.85 3.77 3.19 3.64 3.64 3.64 3.64 3.64 3.64
PV UFCF
SUM PV UFCF -126,931.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -41,292
Terminal Value -2,521,424
Present Terminal Value -2,108,911
Enterprise Value -2,235,842
Net Debt 172,706
Equity Value -2,408,548
Diluted Shares Outstanding, MM 49
Equity Value Per Share -48,933.84

Benefits You Will Receive

  • Pre-Loaded Financial Model: Leverage Towa Pharmaceutical’s actual data for accurate DCF valuation.
  • Comprehensive Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
  • Real-Time Calculations: Automatic updates provide immediate feedback as you adjust inputs.
  • Professional-Grade Template: A polished Excel file crafted for high-quality valuation analysis.
  • Flexible and Reusable: Designed for adaptability, allowing repeated use for in-depth forecasts.

Highlighted Features

  • Accurate Towa Financials: Gain access to reliable historical data and future forecasts specific to Towa Pharmaceutical Co., Ltd. (4553T).
  • Adjustable Forecast Parameters: Modify yellow-highlighted cells, including WACC, growth rates, and profit margins.
  • Real-Time Calculations: Enjoy automatic updates for DCF, Net Present Value (NPV), and cash flow analyses.
  • User-Friendly Dashboard: Intuitive charts and summaries designed to effectively display your valuation findings.
  • Designed for All Skill Levels: An accessible layout tailored for investors, CFOs, and consultants alike.

How It Functions

  1. Download the Template: Gain immediate access to the Excel-based Towa Pharmaceutical DCF Calculator.
  2. Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
  3. Instant Calculations: The model promptly recalculates Towa Pharmaceutical's intrinsic value.
  4. Test Scenarios: Run various scenarios to assess how changes in assumptions affect valuation.
  5. Analyze and Decide: Leverage the results to inform your investment or financial analysis for Towa Pharmaceutical Co., Ltd. (4553T).

Why Opt for This Calculator?

  • Reliable Data: Access accurate financial information for Towa Pharmaceutical Co., Ltd. to ensure trustworthy valuation outcomes.
  • Fully Customizable: Tailor critical variables such as growth rates, WACC, and tax rates to align with your financial forecasts.
  • Efficient: Pre-established calculations eliminate the hassle of starting from the ground up.
  • Professional-Grade Resource: Crafted for investors, analysts, and consultants alike.
  • User-Friendly Design: An intuitive interface and detailed guidance make it accessible for everyone.

Who Can Benefit from This Product?

  • Professional Investors: Develop comprehensive and reliable valuation models for analyzing portfolios involving Towa Pharmaceutical Co., Ltd. (4553T).
  • Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
  • Consultants and Advisors: Deliver precise valuation insights for clients interested in Towa Pharmaceutical Co., Ltd. (4553T).
  • Students and Educators: Utilize real-world data to enhance financial modeling skills and instruction.
  • Healthcare Enthusiasts: Gain insights into the market valuation of pharmaceutical companies like Towa Pharmaceutical Co., Ltd. (4553T).

Contents of the Template

  • Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Towa Pharmaceutical Co., Ltd. (4553T), including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for calculating the Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models illustrating intrinsic value along with comprehensive calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support in-depth analysis.
  • Key Ratios: Includes ratios for profitability, leverage, and efficiency specifically for Towa Pharmaceutical Co., Ltd. (4553T).
  • Dashboard and Charts: Visual representation of valuation results and underlying assumptions for straightforward analysis.


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.